Who is sponsoring NCT04858152?

NCT04858152 is sponsored by Mehdi Rashighi.

What drugs are being tested in NCT04858152?

Interventions in NCT04858152: Follicular Unit Extraction via punch biopsy.

Is NCT04858152 still recruiting?

NCT04858152 is currently withdrawn. Last updated 24 May 2023.

Last reviewed 2023-05-24 · How we verify

NCT04858152

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hair Transplantation for Treatment of Vitiligo

Withdrawn NA Last updated 24 May 2023

What this trial tests

NA trial testing Follicular Unit Extraction via punch biopsy in Vitiligo. Withdrawn.

Timeline

1 August 2021

Primary endpoint
15 August 2022

15 August 2023

Quick facts

Lead sponsor	Mehdi Rashighi
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 August 2021
Primary completion	15 August 2022
Estimated completion	15 August 2023
Sites	1 location across United States

Drugs / interventions tested

Follicular Unit Extraction via punch biopsy

Conditions studied

Vitiligo — all drugs for Vitiligo →

Sponsor

Mehdi Rashighi

Who can join

18 and older, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are several surgical methods to treat vitiligo patches, and follicular unit extraction (FUE) is one among them. FUE, performed using punch biopsy extraction and hair follicle transplantation, has proven safe and effective in multiple studies for treatment of hair bearing (non-glabrous) skin. This technique has not yet been trialed on hairless areas (glabrous skin) affected by vitiligo, such as the lips, fingertips, knuckles, wrists, and feet, which tend to be resistant to standard treatments. We suspect this technique will be successful in patients who have responded well to other therapies in all areas except for non-hair bearing areas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Vitiligo

Currently open trials in the same condition.

NCT07153666 — A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo · recruiting
NCT07267273 — Betamethasone Phonophoresis For Vitiligo · NA · recruiting
NCT07232238 — TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients · active not recruiting
NCT07532330 — Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo · NA · active not recruiting
NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04858152 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mehdi Rashighi
Last refreshed: 24 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04858152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing